Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
This review discusses completed phase II randomized clinical trials with high-quality published results for compounds that demonstrate effects on nonalcoholic steatohepatitis histology (obeticholic acid, elafibranor, and liraglutide). The authors also review the available preliminary data on cenicriviroc and selonsertib, with or without simtuzumab's phase II studies. Finally, the authors briefly discuss compounds that have been tested but did not achieve the primary end point of histologic improvement and appeared in high-quality published articles (cysteamine bitartrate and long-chain polyunsaturated fatty acids).
['Gawrieh|Samer|S|', 'Chalasani|Naga|N|']
D061067:Antibodies, Monoclonal, Humanized D065100:CCR5 Receptor Antagonists D047188:Chalcones D002635:Chenodeoxycholic Acid D017322:Clinical Trials, Phase II as Topic D003543:Cysteamine D065104:Cystine Depleting Agents D006801:Humans D007093:Imidazoles D054795:Incretins D000069450:Liraglutide D065626:Non-alcoholic Fatty Liver Disease D011422:Propionates D047428:Protein Kinase Inhibitors D016032:Randomized Controlled Trials as Topic D013454:Sulfoxides
Obeticholic acid Elafibranor Liraglutide Cenicriviroc Selonsertib NAFLD NASH